BCWorld Pharm

Privately held: no public share price · South Korea

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule
Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathy

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026PresentationCapsaicin (Qutenza)Phase III RISE results at IASP 2026: one of the primary endpoints met (average pain intensity, weeks 2-12)

Financial reports

No financial reports recorded.